Navigation Links
Biopharm Insight’s Respiratory Disease Report Highlights Key Drugs Coming Up for Approval or in Late-Stage Development
Date:11/6/2013

Norwood, MA (PRWEB) November 06, 2013

BioPharm Insight’s Respiratory Disease Report covers key drugs in development in this competitive therapeutic sector. The report is based on primary research and interviews conducted with numerous physicians, investigators and key opinion leaders at the recent European Respiratory Society Annual Congress 2013 in Barcelona, Spain.

In discussing the Respiratory Disease Report, Kirsty Barnes, Biopharm Insight’s Editor EMEA, said, “The report is another example of why decision makers in pharmaceutical R&D or the investment side of drug development rely on BioPharm Insight’s independent investigative journalism, market analytics and key industry contacts to gain competitive insight.”

Some highlights and key takeaways from the report:

  •     Competitive landscape of LABA/LAMA combinations in development to treat COPD
  •     Novartis'combination drug Ultibro Breezhaler for chronic obstructive pulmonary disease (COPD) and US market outlook
  •     Forest and Almirall’s aclidinium bromide/formoterol combination
  •     Boehringer's Spiriva Respimat (tiotropium) mist inhaler in COPD
  •     In idiopathic pulmonary fibrosis (IPF), Novartis’ QAX576, an anti-IL-13 in Phase II development, has been quietly terminated
  •     In asthma, GlaxoSmithKline and partner Theravance are still considering their strategy to progress Breo Ellipta (fluticasone furoate/vilanterol) for US approval.
  •     In pulmonary arterial hypertension (PAH), Actelion will need to get experts engaged in the discussion on Opsumit’s (macitentan) EU pricing. EU approval decision is expected YE.
  •     Bayer is in the planning stages of a Phase IIIb study (RESPITE) evaluating riociguat in PAH for those patients insufficiently treated with phosphodiesterase-5 inhibitors.
  •     PTC Therapeutics' ataluren for cystic fibrosis caused by nonsense mutations (nmCF).

Subscribers to BioPharm Insight received the Respiratory Report on October 15.

Non-subscribers, download the report.

About BioPharm Insight

BioPharm Insight is part of Infinata, a Financial Times Group company, and a leading provider of business intelligence solutions which also include BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.

About Infinata, Inc.

Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Business Inquiries: Holly Burke, hburke[at]infinata[dot]com, 781-619-0131
Media Inquiries: Brenda Nashawaty, Brenda[at]nashawaty[dot]com, 617-688-3253

Read the full story at http://www.prweb.com/releases/2013/11/prweb11300052.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. BioPharm Systems Named to the 2012 Lead411 Technology 200 List
2. BioPharm Systems to Host Webinar on Using iHelp in Oracle’s Siebel Clinical Trial Management System
3. BioPharm Systems to Host Webinar on Clinical Trial Supply Management with Siebel CTMS
4. Nine Lives Media Names BioPharm Systems to the MSPmentor 501
5. BioPharm Systems Unveils Study Data Mapper to Simplify the Preparation and Reporting of Clinical Data
6. Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at ReportsnReports.com
7. Therapure Biopharma Inc. Awarded US Government Contract for Development of Anti-Nerve Gas Agent
8. World Antibiotic Resistance Market Saw Big Changes in Last Five Years, According to Biopharm Reports Study Available at MarketPublishers.com
9. Mass Spectrometry Marketplace Discussed by Biopharm Reports in In-demand Research Study Available at MarketPublishers.com
10. Study says children exposed to tobacco smoke face long-term respiratory problems
11. Study shows antibiotic improves respiratory function in lung transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified ... series of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve ... The series, known as “Mindfulness for Actors and Artists,” has been featured in ...
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services ... of Eastern Michigan last Friday in order to aid in the Flint water crisis. ... include a facility located in Clio, only 15 miles away from Flint. , “We ...
(Date:2/10/2016)... California (PRWEB) , ... February 10, 2016 , ... ... are working together to expand dental health services to the developmentally disabled in ... We Care Dental’s operations to a new facility at 71-949 Highway 111, Suite ...
(Date:2/10/2016)... ... 10, 2016 , ... As part of its ongoing series of aquatic therapy ... webinar features a dynamic expert and thoughtful presentation to give attendees a better sense ... Both events are free to attend, but registration is required. , Rehabilitation ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in partnership ... Grand Challenge to generate a biomarker to track TDP43 aggregation. ... up to a $1 million investment. ... disease that affects nerve cells in the brain and the ... initiate and control muscle movement, which often leads to total ...
(Date:2/10/2016)... 10, 2016 Convergence scenarios are ... various technologies that results in diverse solutions ... opportunities create a cyclical system where technology ... the development of new technologies. ... technology convergences, which are constantly fostering new ...
Breaking Medicine Technology: